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Abstract
Background: Achieving adequate antimalarial drug exposure is essential for curing malaria. Day 7 blood or
plasma lumefantrine concentrations provide a simple measure of drug exposure that correlates well with
artemether-lumefantrine efficacy. However, the ‘therapeutic’ day 7 lumefantrine concentration threshold needs
to be defined better, particularly for important patient and parasite sub-populations.
Methods: The WorldWide Antimalarial Resistance Network (WWARN) conducted a large pooled analysis of individual
pharmacokinetic-pharmacodynamic data from patients treated with artemether-lumefantrine for uncomplicated
Plasmodium falciparum malaria, to define therapeutic day 7 lumefantrine concentrations and identify patient factors
that substantially alter these concentrations. A systematic review of PubMed, Embase, Google Scholar, ClinicalTrials.gov
and conference proceedings identified all relevant studies. Risk of bias in individual studies was evaluated based on
study design, methodology and missing data.
Results: Of 31 studies identified through a systematic review, 26 studies were shared with WWARN and 21
studies with 2,787 patients were included. Recrudescence was associated with low day 7 lumefantrine concentrations
(HR 1.59 (95 % CI 1.36 to 1.85) per halving of day 7 concentrations) and high baseline parasitemia (HR 1.87 (95 % CI 1.22
to 2.87) per 10-fold increase). Adjusted for mg/kg dose, day 7 concentrations were lowest in very young children
(<3 years), among whom underweight-for-age children had 23 % (95 % CI −1 to 41 %) lower concentrations than
adequately nourished children of the same age and 53 % (95 % CI 37 to 65 %) lower concentrations than adults. Day 7
lumefantrine concentrations were 44 % (95 % CI 38 to 49 %) lower following unsupervised treatment. The
highest risk of recrudescence was observed in areas of emerging artemisinin resistance and very low
transmission intensity. For all other populations studied, day 7 concentrations ≥200 ng/ml were associated
with >98 % cure rates (if parasitemia <135,000/μL).
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Conclusions: Current artemether-lumefantrine dosing recommendations achieve day 7 lumefantrine
concentrations ≥200 ng/ml and high cure rates in most uncomplicated malaria patients. Three groups are at
increased risk of treatment failure: very young children (particularly those underweight-for-age); patients with
high parasitemias; and patients in very low transmission intensity areas with emerging parasite resistance. In
these groups, adherence and treatment response should be monitored closely. Higher, more frequent, or prolonged
dosage regimens should now be evaluated in very young children, particularly if malnourished, and in patients with
hyperparasitemia.
Keywords: Artemether-lumefantrine, Day 7 lumefantrine concentration, Pharmacokinetic, Pharmacodynamic,
Uncomplicated Plasmodium falciparum malaria, Baseline parasitemia, Malnutrition, Early parasitological response, Drug
resistance, Meta-analysis
Background
The World Health Organization (WHO) recommends
artemisinin-based combination therapies (ACTs) for treat-
ing uncomplicated Plasmodium falciparum malaria [1]. In
order to prolong their useful therapeutic life until effective
novel antimalarials become available, optimal use and
dosing of widely used ACTs is essential. This can only
be achieved by accurately defining the therapeutic drug
exposure thresholds, which enables identification of
vulnerable populations in whom current dosing recom-
mendations do not consistently achieve effective drug
exposure. Therapeutic responses are mainly determined
by density and susceptibility of the infecting malaria
parasites and drug exposure, although acquired host
immunity can compensate for failing treatments. For
combination therapies, the early parasitological response is
determined largely by the artemisinin component. To pre-
vent recrudescence, the malaria parasites that remain after
exposure to the artemisinin component for two 48-hr asex-
ual cycles must be cleared by the slowly eliminated partner
drug [2]. The precise pharmacokinetic (PK) determinants
of treatment outcome in uncomplicated malaria remain
uncertain, but the area under the blood or plasma con-
centration-time curve (AUC) and the concentration on
day 7 of slowly eliminated antimalarials are considered im-
portant predictors [2, 3].
Artemether-lumefantrine accounted for 73 % of ACTs
procured in 2013 [4]. Lumefantrine has variable bioavail-
ability, largely due to fat-dependent absorption, with
high plasma protein binding (mainly to high-density li-
poproteins) and is extensively metabolized in the liver,
primarily by the CYP3A4 enzymes [1]. Lumefantrine
concentration on day 7 has been shown to be the most
important single concentration measure, in terms of its
correlation with the area under the concentration time
curve and its association with treatment response [3, 5, 6].
The ‘therapeutic’ day 7 lumefantrine concentrations pub-
lished to date range from 170 ng/ml to 500 ng/ml [6–12],
and were defined mostly from individual studies with
small numbers of treatment failures. Lower lumefantrine
exposure has been described in young children [9], preg-
nant women [13–17], smokers [15], or when artemether-
lumefantrine is taken unsupervised [9], without fat [18] or
with concurrent efavirenz [19–21], rifampicin [22] or mef-
loquine [23]. However, the extent to which this compro-
mises efficacy is poorly defined, and no dose optimization
studies have been published in any of these important
target populations.
While there are more studies published on the pharma-
cokinetics of lumefantrine than any other antimalarial, the
individual studies published to date are not sufficient to
develop optimal evidence-based dosage recommendations
for all major target population groups. The objective
of this analysis was to define therapeutic day 7 blood
or plasma lumefantrine concentrations for artemether-
lumefantrine treatment of uncomplicated P. falciparum
malaria and to identify patient factors that cause substan-
tial changes to these lumefantrine concentrations. For a
drug with an overall high efficacy, this requires a very large
sample set, which is most efficiently achieved by pooling
available data. In addition to increasing power, using in-
dividual patient data allows for standardization of data
curation and analysis.
Methods
Data acquisition
Relevant studies were identified by searching PubMed,
Embase, Google Scholar, ClinicalTrials.gov and confer-
ence proceedings using the key words ‘lumefantrine
pharmacokinetics’ or ‘lumefantrine concentrations’ and
‘clinical study’. Participating authors agreed to the World-
Wide Antimalarial Resistance Network (WWARN) terms
of submission [24], which ensure that all data uploaded
were anonymized and obtained with informed consent,
and in accordance with any laws and ethical approvals ap-
plicable in the country of origin. The WWARN automated
data management, curation and analysis tools converted
submitted data into a set of defined data variables in a
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standard format, following the WWARN clinical and
pharmacology data management and statistical analysis
plans [25, 26]. Study reports generated from the for-
matted datasets were sent back to investigators for
validation or clarification.
For the analyses reported here, any study of non-
pregnant patients with uncomplicated P. falciparum
malaria (including mixed infections) treated with a 2- or
3-day artemether-lumefantrine regimen, and with a blood
or plasma lumefantrine concentration measurement avail-
able on day 7, was eligible for inclusion. Pregnant women
were not included as all nine recrudescences in pregnant
women were observed in one study in Thailand [16],
the only study where lumefantrine concentrations were
measured in capillary plasma – precluding disaggrega-
tion of the effects of pregnancy and sample matrix on
the pharmacokinetic-pharmacodynamic (PK-PD) rela-
tionship. The effects of pregnancy on artemether-
lumefantrine exposure have been published previously
[8, 13–16].
Patients with a quantifiable pre-dose lumefantrine
concentration were excluded from the analysis of determi-
nants of day 7 lumefantrine concentration. Studies on
re-treatment of treatment failures, or a protocol follow-up
period of less than 28 days, or Polymerase Chain Reaction
(PCR) results unavailable/indeterminate, were excluded
from the outcome analysis (Fig. 1). For the full list of stud-
ies [5, 7, 11, 12, 27–44] and assay methods [7, 45–51]
used, see Additional file 1: Table S1.
Ethical approval
All data included in this analysis were obtained after
ethical approvals from the countries of origin. Ethical
approval to conduct individual participant data meta-
analyses was granted by the Oxford Tropical Research
Ethics Committee (OxTREC), and OxTREC ruled that
Fig. 1 Study profile. PK, pharmacokinetic; LLOQ, Lower limit of quantification
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appropriate informed consent had been met by each
study.
Statistical analysis
All analyses were carried out according to the a priori
statistical analysis plan [52].
Total dose was calculated from the recorded number
of tablets administered per dose for each patient, if this
information was available. If no individual patient dosing
data was available, dose was estimated using the proto-
col dosing schedule. All studies in children used weight-
based dosing. Treatment was classified as: supervised if
all doses had been directly observed; partially supervised
if at least the three morning doses had been observed;
and not supervised if fewer doses were observed.
A lumefantrine concentration was considered as taken
on day 7 if the sample time was recorded as between
144 and 196 hours, inclusive, or as day 6, 7 or 8 after
starting artemether-lumefantrine treatment. If multiple
concentrations were available within this time interval,
the measurement closest to 168 hours was selected. Day
7 concentrations below the lower limit of quantification
(LLOQ) were replaced by values half of the limit of
quantification [53] (for individual study limits of quanti-
fication, see Additional file 1: Table S1). Factors affecting
log-transformed lumefantrine concentration on day 7
were investigated using normal regression with random
effects for study site in patients treated with the standard
artemether-lumefantrine regimen of six doses; those
with lumefantrine concentrations > LLOQ before treat-
ment were excluded from this analysis. As treatment
supervision is a study-level variable and does not corres-
pond to individual patient compliance with treatment it
can mask the effects of other variables, so two multivari-
able models were fitted: one on all patients, adjusting for
whether treatment administration was supervised or not;
and another only on patients who received supervised
treatment.
Age was analyzed as a categorical variable using <1, 1–4,
5–11 and 12+ years as categories, since pharmacokinetic
parameters change with age in children but generally not in
adults, and as treatment response improves as premunition
is acquired with age in areas of moderate to high malaria
transmission intensity. Further categorization in children
younger than 5 years of age (1–2 and 3–4 years) was based
on heterogeneity of the results; adjusted for dose and other
factors, day 7 concentrations were different in these two
groups (see Results, Additional file 2: Figure S1, Additional
file 3: Figure S2, Table 2).
The hemoglobin cut-offs for moderate anemia were <10 g/
dL in children under 5 years of age and <11 g/dL in older
patients, and for severe anemia were <7 and <8 g/dL,
respectively [54]. The following conversion from hematocrit
was used: hemoglobin = (hematocrit-5.62)/2.60 [55].
The nutritional status of children under 5 years of age
was calculated as a weight-for-age Z-score (WAZ), using
the ‘igrowup’ package developed by WHO [56]. Those
with WAZ under −2 (below the 3rd centile) were classi-
fied as underweight-for-age (termed ‘underweight’).
Transmission intensity was classified as very low, low,
moderate or high, based on triangulation of information
given in the original publication(s), observed PCR-
confirmed reinfection rates, and the malaria endem-
icity estimates obtained for study sites and year from
the Malaria Atlas Project [57] (Additional file 4: Table S2).
Slow early parasitological response was defined as the loge
parasite reduction rate at 48 hours (PRR48) <5 (provided a
positive count was recorded on day 2), based on the distri-
bution of PRR48 in all patients, or as parasite positivity
by microscopy on day 3 [58]. Parasitological response
in patients with a negative, or no count, on day 2 and a
negative, or no count, on day 3 were classified as unknown.
WHO definitions of therapeutic efficacy outcome [59]
were used. Risk factors for PCR-confirmed P. falciparum
recrudescence and re-infection were examined in two
separate analyses. In each analysis, patients with recur-
rence of P. falciparum parasitemia but PCR-confirmed
outcome other than the one of interest (for example
re-infection in the recrudescence analysis) and patients
with a P. vivax infection were censored at the time of re-
currence. Patients without a PCR genotyping result were
excluded to avoid informative censoring. Cox proportional
hazards regression was used to model the relationship be-
tween treatment outcome and lumefantrine concentration
on day 7 and other pre-defined covariates. Random effects
in the form of frailty parameters were used to adjust for
study site effects [60]. The proportional hazard assump-
tion was tested based on Schoenfeld residuals [61] and, in
the case of non-proportionality, interactions with the cate-
gorized time variable were used to account for changing
effects over time. Fractional polynomials [62] were used to
explore possible non-linear forms of continuous variables;
the best transformation was linear logarithmic for both
lumefantrine concentration and parasitemia.
Pre-defined variables specified in the statistical analysis
plan [52] were examined for inclusion in the final models
in a stepwise forward fashion. Inclusion of covariates in
the final model was based on whether they improved the
overall model (likelihood ratio test), changed the coeffi-
cient estimates for other factors and examination of the
residuals.
Risk of bias within studies was assessed based on: 1)
study design (randomization, sequence generation, blind-
ing); 2) methodology for outcome classification (assay
methodology and limit of quantification for measure-
ment of lumefantrine concentration on day 7, and PCR
methodology for assessing treatment outcome); and 3)
the number and proportion of patients with (a) missing
WorldWide Antimalarial Resistance Network (WWARN)
Lumefantrine PK/PD Study Group BMC Medicine  (2015) 13:227 
Page 4 of 19
outcomes (missing concentration on day 7, incomplete
follow-up (<28 days), missing PCR results) and (b)
missing baseline covariates (age, weight, parasitemia,
temperature, hemoglobin/hematocrit, treatment super-
vision, dose administration with fat). For the final re-
crudescence model, two sets of sensitivity analyses
were performed. Firstly a model was refitted with each
study’s data excluded, one at a time, and a coefficient of
variation around the parameter estimates calculated. This
would identify any influential studies, that is, studies with
unusual results (due to variations in methodology, patient
population, and so on) that affect the overall pooled ana-
lysis findings. Secondly, to assess the impact of missing
PCR data, an unknown outcome was imputed 20 times as-
suming the same proportion of recrudescent to new infec-
tions as observed in patients with known outcome; the
model was refitted each time and imputation estimates
and their 95 % CI were calculated [63].
Results
Data summary
WWARN received and curated data from 26
artemether-lumefantrine pharmacokinetic studies of
6,229 malaria patients in 12 countries in Africa and
Asia (Fig. 1, Additional file 1: Table S1). In the initial
search carried out in December 2012, a further four
studies were identified [10, 64–66] and investigators
invited to participate, but their data was not deposited
in the WWARN repository so could not be included (one
study was contributed after the analysis was completed).
The last bibliographic search carried out in December
2014 identified another recent relevant study [13], when it
was too late to include in the analysis.
Five studies were excluded as they were studies of
pregnant women, did not collect day 7 pharmacokinetic
samples or evaluated a five-day artemether-lumefantrine
regimen (Fig. 1). Among the 21 artemether-lumefantrine
therapeutic efficacy studies included in this analysis,
lumefantrine concentrations on day 7 were available for
2,787 patients (Fig. 1, Additional file 1: Table S1), com-
prising: 82 infants (median 8 months); 1,188 children
aged 1–4 years (median 3 years); 564 children aged 5–11
years (median 8 years); and 953 non-pregnant patients
aged ≥12 years termed ‘adults’ (range = 12–87 years,
IQR = 16 to 30, with 99 % <60 years of age). Among the
children aged <5 years, 220/1,269 (17 %) were
underweight-for-age (termed ‘underweight’), with a me-
dian WAZ of −2.6 (range = −5.3 to −2.0; IQR = −3.1 to
−2.27). There were no important clinical differences in
baseline characteristics between patients with pharmaco-
kinetic data (from 3 % to 100 % across studies) and the
patients in these studies in whom day 7 lumefantrine
concentrations were not measured (Table 1). Almost all
patients had been treated with Novartis Coartem® tablets
(2,756/2,787; 99 %), with very few (31/2,787; 1 %) given
Novartis Coartem® Dispersible tablets; none had been
treated with a generic artemether-lumefantrine formulation.
Dosage regimen
The majority of patients (2,641/2,787; 95 %) were treated
with the current WHO recommended six-dose artemether-
lumefantrine regimen administered over 3 days (60 hours).
The median (range) of the total body weight-adjusted dose
received was: 90 (45–144) mg/kg for infants; 65 (38–111)
mg/kg for children aged 1–4 years; 72 (48–111) mg/kg for
children aged 5–11 years; and 58 (19–108) mg/kg for pa-
tients aged 12 years or older (Additional file 2: Figure S1).
Underweight children aged 1 to 2 years received higher
mg/kg doses than better nourished children of the same
age (80 (38–111) mg/kg compared to 65 (38–97) mg/kg;
P <0.001). However, the opposite was seen in 4-year-old
children (60 (45–90) mg/kg compared to 82 (48–111)
mg/kg; P <0.001), as the better nourished 4-year-olds
usually received the two-tablet dose recommended for
the weight band 15–24 kg, while underweight 4-year-
olds only received the one-tablet dose recommended
for the 5–14 kg weight band, as all underweight chil-
dren weighed <14 kg (Additional file 2: Figure S1). Two
alternative regimens (termed ‘non-standard treatment’)
were also investigated in adults; in these studies the total
recommended dose was given as single daily doses for
3 days (n = 19) or 2/3 of the recommended dose was given
as four doses over 2 days (n = 127).
Day 7 lumefantrine concentrations
Day 7 lumefantrine concentrations were measured either
in venous plasma (n = 1,395 (50 %); 16 studies), capillary
whole blood dried on filter paper (n = 848 (29 %); 5 studies)
or venous whole blood dried on filter paper (n = 544
(19 %); 2 studies) (Additional file 1: Table S1, Additional file
3: Figure S2, Additional file 5: Figure S3). The coefficient of
variation of the day 7 lumefantrine concentration (on log
scale) by study, after adjusting for mg/kg dose administered,
was highest in capillary blood on filter paper ranging be-
tween 43–240 %, compared to 24–27 % in venous blood on
filter paper and 23–70 % in venous plasma. Hemoglobin
was only associated independently with lumefantrine
concentrations measured in capillary whole blood samples.
For blood collected on filter paper, most assays (97 %) had
LLOQ ≥25 ng/ml, while measurements in venous plasma
were more sensitive (LLOQ ≤5 ng/ml for 56 % of samples).
For lumefantrine concentrations measured in capillary
blood on filter paper, 8 % were below the limit of quan-
tification (BLQ), while only 1 % of those in venous
plasma or in venous blood on filter paper were BLQ.
The majority of children under 5 years of age (59 %)
had lumefantrine concentrations measured in capillary
blood, while these were measured in venous plasma for
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the majority of older patients (60 %). Additional file 5:
Figure S3 shows the distribution of measured concen-
trations by study.
The exact time of the lumefantrine concentration sam-
ple collection was available in 384 (14 %) patients, with
a median of 166 (IQR = 164 to 168) hours. The protocol
time in hours was known in 33 (1 %) patients, while in
the remaining patients only the day of measurement was
recorded. Pre-dose lumefantrine concentrations were
measured in 676/2,787 (24.3 %) patients in five studies;
these were assumed to be BLQ in studies without pre-
dose concentrations measured. After excluding patients
with quantifiable lumefantrine concentrations before the
first dose (n = 67/676; 9.9 %), the lowest day 7 dose-
adjusted lumefantrine concentrations were measured in
capillary blood (Additional file 3: Figure S2).
Determinants of day 7 lumefantrine concentration
In patients treated with the standard six-dose regimen
and without quantifiable lumefantrine concentrations
before the first dose (Fig. 1), the independent factors
associated with lower day 7 lumefantrine concentra-
tions (Table 2) were: unsupervised (including partially
supervised) treatment (43.8 % (95 % CI 38.0 to 49.1 %)
lower than supervised treatment); age (infants had 38.1 %
(95 % CI 21.7 to 51.1 %), children aged 1–2 years had
41.4 % (95 % CI 32.7 to 48.9 %) and children aged 3–4
years had 20.9 % (95 % CI 9.4 to 30.9 %) lower concentra-
tions than adults); and fever on admission (13.5 % (95 %
CI 6.4 to 20.1 %) lower than patients with only a history
of fever). As fat was co-administered with artemether-
lumefantrine doses in the majority of patients (n = 2,185,
85 %), no fat effect was detected (P = 0.943). Within the
time window studied (days 6 to 8), the lumefantrine con-
centration declined by 36.6 % (95 % CI 13.1 to 53.7 %) per
day, which corresponds to a terminal half-life of 37 (95 %
CI 22 to 118) hours. The effect of body weight-adjusted
(mg/kg) dose was relatively small, increasing the day 7
lumefantrine concentration by 9.8 % (95 % CI 4.0 to
15.9 %) for each 20 mg/kg increase in total lumefantrine
Table 1 Baseline characteristics of patientsa with and without day 7 lumefantrine concentrations
Parameter Patients with day 7 lumefantrine concentration Patients without day 7 lumefantrine concentration P valueb
N Median (range) or N (%) N Median (range) or N (%)
Age (years) 2,786 6.2 (0.3 to 86.7) 2,805 5.5 (0.2 to 80.0) 0.028
Age category <0.001
< 1 year 82 (3.0) 107 (3.8)
1–2 years 573 (20.6) 590 (21.0)
3–4 years 615 (22.1) 604 (21.5)
5–11 years 564 (20.2) 852 (30.4)
≥ 12 years 953 (34.2) 652 (23.2)
Weight (kg) 2,786 18.5 (5.0 to 150.0) 2,797 17.0 (5.0 to 97.0) 0.104
Underweightc 1,269 220 (17.3) 1,299 218 (16.8) 0.211
Total dose (mg/kg) 2,764 65.5 (19.2 to 144.0) 2,786 65.5 (20.9 to 144) 0.092
Treatment supervision 2,787 2,788 <0.001
Fully 1,971 (70.7) 1,644 (59.0)
Partially 115 (4.1) 602 (21.6)
Unsupervised 701 (25.2) 542 (19.4)
Co-administration with fat 2,787 2,809 0.147
Yes/advised 2,204 (79.1) 1,752 (62.4)
Not stated 583 (20.9) 1,057 (37.6)
Parasitemia (/μl) 2,767 17,140 (16 to 524,414) 2,799 18,120 (10 to 862,400) 0.021
Temperature (°C) 2,662 37.7 (34.3 to 41.9) 1,967 37.5 (35.0 to 41.5) <0.001
Hemoglobin (g/dL) 2,068 10.6 (4.8 to 25) 1,484 11.3 (4.2 to 17.9) 0.428
Sex (female) 2,787 1,281 (46.0) 2,805 1,278 (45.6) 0.857
Gametocytes present 2,418 112 (4.9) 1,654 92 (5.6) 0.797
Moderate anemia 2,507 1,132 (45.1) 1,484 516 (34.8) 0.016
Severe anemia 2,507 155 (6.2) 1,484 57 (3.8) 0.056
aPatients enrolled in the 21 studies included in the pooled analysis; badjusted for study site in a random effects model; cdefined using a weight-for-age Z-score
(WAZ) < −2 in children <5 years of age
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Table 2 Determinants of day 7 lumefantrine concentrations in non-pregnant patients treated with the six-dose
artemether-lumefantrine regimen
N (n)a Change (%) (95 % CI) P value
Univariable model
Dose (mg/kg) 2,551 0.3 (0.1 to 0.6) 0.010
Co-administration with fat 2,574 (2,185) −1.0 (−28.2 to 26.2) 0.943
Unsupervised administrationb 2,574 (816) −45.4 (−50.6 to −39.6) <0.001
Age
< 1 year 82 −37.7 (−50.5 to −21.6) <0.001
1–2 years 562 −46.5 (−53.5 to −38.5) <0.001
3–4 years 597 −26.1(−35.7 to −15.1) <0.001
5–11 years 534 −3.4 (−12.6 to 6.9) 0.507
12+ years 799 Reference
Sample matrix
Capillary bloodc 848 −38.2 (−54.0 to −22.4) <0.001
Venous bloodc 544 18.5 (−34.7 to 71.8) 0.458
Venous plasma 1,182 Reference
Day of samplingd 2,574 −36.8 (−56.6 to −17.0) 0.004
Fevere 2,426 (1,054) −17.4 (−24.0 to −10.8) <0.001
Hemoglobinf 2,200 1.0 (−0.8 to 2.8) 0.272
Baseline parasitemia (log10) 2,554 −8.8 (−13.3 to −4.1) <0.001
WAZg 1,240 3.2 (−1.7 to 8.0) 0.191
UWAh 1,240 (215) −4.5 (−19.1 to 10.2) 0.559
Multivariable modeli
Dose (mg/kg) 2,422 0.5 (0.2 to 0.7) 0.001
Unsupervised administrationb 2,422 (795) −43.8 (−49.1 to −38.0) <0.001
Day of samplingd 2,422 −36.4 (−53.6 to −12.9) 0.005
Fevere 2,422 (1,052) −13.5 (−20.1 to −6.4) <0.001
Baseline parasitemia (log10) 2,422 −5.1 (−9.8 to −0.1) 0.045
Age
< 1 year 82 −38.1 (−51.1 to −21.7) <0.001
1–2 years 555 −41.4 (−48.9 to −32.7) <0.001
3–4 years 594 −20.9 (−30.9 to −9.4) 0.001
5–11 years 508 −6.6 (−16.1 to 4.0) 0.215
12+ years 683 Reference
Multivariable model – supervised administration onlyj
Dose (mg/kg) 1,562 0.4 (0.1 to 0.7) 0.007
Day of samplingd 1,562 −43.0 (−60.1 to −18.6) 0.001
Sample matrixk
Capillary bloodc 366 −15.2 (−31.0 to 4.3) 0.119
Venous bloodc 541 1.4 (−23.2 to 34.0) 0.921
Venous plasma 655 Reference
Hemoglobin
Capillary bloodc 366 −5.4 (−9.0 to −1.7) 0.005
Venous bloodc 541 2.4 (−1.5 to 6.4) 0.229
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dose. After adjusting for these factors in a multivariable
model (Table 2), assay matrix sampled (venous plasma or
capillary or venous blood on filter paper) did not signifi-
cantly alter the day 7 lumefantrine concentrations.
Among patients given supervised treatment with a stand-
ard six-dose regimen (Table 2), after adjusting for the other
covariates, including body weight-adjusted (mg/kg) dose,
adequately nourished children aged 3–4 years had 17.5 %
(95 % CI 3.6 to 29.4 %) lower concentrations than adults,
while those aged <3 years had 38.6 % (95 % CI 28.2 to
47.5 %) lower concentrations. The effect of nutritional
status was apparent in children <3 years of age; those who
were underweight had a 23.2 % (95 % CI −0.7 to 41.4 %)
lower concentration than adequately nourished children in
the same age group (P = 0.057) and a 52.8 % (95 % CI 36.5
to 65.0 %) lower concentration than all adults (P <0.001).
However, this association of lumefantrine concentration
with nutritional status was not observed in children aged 3
or 4 years old (P = 0.881). Very young children, particularly
those who were underweight, not only had lower lume-
fantrine concentrations compared to older patients for
a given total mg/kg dose (Fig. 2, Table 2), but these
Table 2 Determinants of day 7 lumefantrine concentrations in non-pregnant patients treated with the six-dose
artemether-lumefantrine regimen (Continued)
Venous plasma 655 −1.8 (−4.2 to 0.7) 0.163
Fevere 1,562 (590) −12.2 (−19.3 to −4.4) 0.003
Baseline parasitemia (log10) 1,562 −6.1 (−10.7 to −1.4) 0.012
Age
< 3 years old UWAh 28 −52.8 (−65.0 to −36.5) <0.001
Not UWA 262 −38.6 (−47.5 to −28.2) <0.001
3–4 years old UWAh 48 −19.5 (−35.8 to 1.0) 0.061
Not UWA 229 −17.5 (−29.4 to −3.6) 0.015
5–11 years old 399 −2.0 (−11.5 to 8.5) 0.881
≥ 12 years old 596 Reference
aN, total number of patients with non-missing data; n, number of patients with this characteristic; bunsupervised administration includes five studies with no
supervised doses and two studies with the three morning doses supervised; ccollected on filtered paper; dper day, evaluated between days 6 and 8; edefined as
axillary temperature >37.5 °C on enrolment; fno statistically significant association was found when stratified by sample matrix; P for interaction = 0.435; gWorld
Health Organization (WHO) Child Growth Standards weight-for-age Z-score (WAZ) in children <5 years of age; hdefined using a WAZ < −2 in children <5 years of
age; i151 out of 2,574 patients were excluded from this model due to missing information on dose (23) and fever (148); j131 out of 1,758 patients with supervised
treatment were excluded from this model due to missing information on dose (3), fever (127), UWA status (1) or hemoglobin (65); kcomparison at mean value of
hemoglobin of 11 g/dL
Fig. 2 Measured day 7 lumefantrine concentrations in patients given supervised treatment with the recommended six-dose artemether-
lumefantrine regimen, by age and nutrition status. Concentrations are dose-adjusted and scaled for a total dose of 72 mg/kg (after excluding
patients with quantifiable lumefantrine concentrations pre-treatment). Outside values are not shown
WorldWide Antimalarial Resistance Network (WWARN)
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lower concentrations occurred despite their actual mg/kg
dose administered being higher (Additional file 2: Figure
S1). Among the 318 children under 3 years of age with su-
pervised treatment administration, 91 (29 %) had day 7
concentrations below 200 ng/ml compared to 129/1,440
(9 %) older children and adults. This risk was highest
among the underweight children under 3 years of age, of
whom 13/31 (42 %) had day 7 concentrations below
200 ng/ml. The lower concentrations measured in this age
group were consistent across regions and assay matrices.
Day 7 lumefantrine concentration and clinical outcome
After excluding one study on artemether-lumefantrine
retreatment of treatment failures and patients without a
defined treatment outcome, the association between day
7 lumefantrine concentrations and treatment response
was evaluated in 2,528 patients in 20 studies (Fig. 1).
Protocol follow-up time varied between 28 and 63 days;
101 patients (3.9 %) were lost to follow-up before day
28. During the follow-up period, 564 recurrent parasite-
mias were recorded: 321 within 28 days of follow-up;
221 between days 29 and 42; and 62 between days 43
and 63. Among these, there were: 73 P. falciparum re-
crudescences; 376 new P. falciparum infections (196 after
day 28); 112 P. vivax infections; and three infections
with another Plasmodium species. Forest plots showing
individual study estimates of the risks of recrudescence
and reinfection by day 28 and day 42 are presented in
Additional file 6: Figure S4 and Additional file 7: Figure
S5, respectively.
P. falciparum recrudescence
The main predictors of recrudescence were high baseline
parasitemia and low lumefantrine concentration on day 7
(Fig. 3, Table 3). The estimates of the hazard ratios (HRs)
for lumefantrine concentration and parasitemia were very
robust; the HR coefficient of variation, after exclusion of
one study at a time, was 1.9 % and 5.9 %, respectively.
In the multivariable model (Table 3), the highest risk
of recrudescence (HR 13.44; 95 % CI 2.51 to 72.02; P =
0.002) was observed in one study in a low transmission
setting in Cambodia (2003–2004; n = 79), where delayed
early parasitological response was observed and artemi-
sinin resistance subsequently confirmed. An increased
risk of recrudescence (HR 5.63; 95 % CI 1.10 to 28.92;
P = 0.039) was also observed in the very low transmission
areas studied (n = 66, two studies, both in Thailand). The
increased risk of recrudescence in these areas was still
observed after adjusting for slow early parasitological
responses in 65 of 2,527 patients, who had an almost 3-
fold higher risk of recrudescence (HR 2.72; 95 % CI
1.04 to 7.16; P = 0.014) compared to those with faster
parasite clearance.
Within the low transmission areas, the small number
of recrudescences precluded any meaningful comparisons
between age categories. In the moderate/high transmission
areas, the increased risk of recrudescence in children aged
1–4 years old was not statistically significant (HR 1.37;
95 % CI 0.46 to 4.11). However, after adjusting for their
day 7 lumefantrine concentrations, the risk of recrudes-
cence appeared to increase with a decrease in the weight-
for-age Z-score (WAZ), but this did not reach statistical
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Fig. 3 Predicted day 7 lumefantrine concentrations needed to achieve a 95 % cure rate by day 42. Results are derived from multivariable Cox
regression model (Table 3) for key patient populations. A zero study site effect was assumed. TIA, transmission intensity area
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Table 3 Cox regression analysis of risk of recrudescence by day 42
Parameter Patientsa Eventsa HR (95 % CI) P value
Univariable model
Day 7 lumefantrine concentration (log2)
Allb 2,528 70 0.64 (0.55 to 0.74) <0.001
Venous plasma 1,336 46 0.56 (0.46 to 0.69) <0.001
Capillary bloodb 663 21 0.68 (0.54 to 0.84) 0.001
Venous bloodb 529 3 0.84 (0.16 to 4.34) 0.559
Age (years) 2,528 70 1.01 (0.99 to 1.04) 0.22
Age categoryb
< 1 year 73 2 0.32 (0.06 to 1.59) 0.162
1–4 years 1,004 29 0.55 (0.23 to 1.31) 0.177
5–11 years 540 4 0.39 (0.13 to 1.21) 0.103
12+ years 911 32 Reference
Sex (female) 2,528 (1,157) 70 (32) 1.33 (0.82 to 2.16) 0.254
Baseline parasitemia (log10) 2,527 70 1.85 (1.33 to 2.76) 0.003
Baseline temperature (°C) 2,384 56 1.17 (0.93 to 1.46) 0.181
Baseline feverc 2,384 (1,049) 56 (36) 1.49 (0.84 to 2.64) 0.177
Baseline gametocytemia 2,197 (109) 53 (4) 1.69 (0.58 to 4.94) 0.335
Hemoglobinb 2,189 57 1.01 (0.90 to 1.14) 0.857
Moderate anemia 2,279 (1,022) 58 (25) 0.78 (0.44 to 1.39) 0.402
Severe anemia 2,279 (138) 58 (6) 1.23 (0.51 to 2.99) 0.642
WAZ 1,076 34 0.92 (0.70 to 1.21) 0.538
Underweight d 1,076 34 1.36 (0.61 to 3.03) 0.457
Palpable spleen 1,732 (272) 35 (8) 1.25 (0.56 to 2.78) 0.581
Palpable liver 1,732 (102) 35 (5) 1.19 (0.43 to 3.29) 0.732
<Six-dose artemether-lumefantrine regimen 2,528 (142) 70 (15) 5.32 (1.97 to 14.39) <0.001
D2 Parasite positive count 1,901 (179) 47 (17) 3.12 (1.55 to 6.25) 0.001
D3 Parasite positive count 2,153 (23) 51 (5) 5.29 (1.78 to 15.76) 0.003
Log of PRR48e 1,897 47 0.86 (0.76 to 0.97) 0.011
Early parasitological responsef
Fast 1,193 36 Reference
Slow 65 8 2.98 (1.25 to 7.07) 0.014
Unknown 1,270 26 1.05 (0.54 to 2.06) 0.879
Transmission intensity areas (TIA)b
Very low 66 9 6.52 (1.28 to 33.23) 0.024
Low 500 23 1.74 (0.59 to 5.09) 0.314
Moderate 738 12 0.83 (0.23 to 2.94) 0.769
High 1,224 26 Reference
Multivariable modelg
Day 7 lumefantrine concentration (log2) 2,527 70 0.63 (0.54 to 0.73) <0.001
Baseline parasitemia (log10) 2,527 70 1.87 (1.22 to 2.87) 0.004
Location/transmission intensity area (TIA)
Cambodia 77 10 13.44 (2.51 to 72.02) 0.002
Very low TIA 66 9 5.63 (1.10 to 28.92) 0.039
Low TIA 423 13 1.32 (0.34 to 5.07) 0.69
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significance (HR 1.26; 95 % CI 0.94 to 1.69; P = 0.12 per
unit decrease, which corresponds to a doubling of the re-
crudescence risk (HR 2.01; 95 % CI 0.83 to 4.83) for a
young child with a WAZ of −3, when compared to an ad-
equately nourished child with a WAZ of 0).
This multivariable model (Table 3) predicts that a day
7 lumefantrine concentration of at least 200 ng/ml was
sufficient to achieve 95 % cure rates in all patients, in-
cluding infants, in low, moderate and high transmission
intensity areas, provided the baseline parasitemia was
below 135,000 parasites/μl. However, in Cambodia and the
areas of very low transmission intensity studied, concentra-
tions ≥1,000 ng/ml (depending on baseline parasitemia)
were required (Fig. 3).
P. falciparum re-infection
A 2-fold increase in (or doubling of ) day 7 lumefantrine
concentrations was associated with a 30 % reduction in
the risk of reinfection (Table 4); however, this was not
constant over the follow-up period. The effect of day 7
lumefantrine concentration remained apparent for lon-
ger when measured in plasma than if measured in capil-
lary or venous blood collected on filter paper (28 versus
21 days), which is consistent with the lower sensitivity of
the filter paper assays (Additional file 1: Table S1). Not
surprisingly given lumefantrine’s elimination half-life, no
association between day 7 concentration and the risk of
reinfection was observed after day 28 (HR 1.02; 95 % CI
0.90 to 1.16; P = 0.735). These results were confirmed by
the sensitivity analyses, when each study was excluded
in turn.
As expected, patients in high transmission areas had a
higher risk of reinfection overall than patients in other
areas (HR 5.76; 95 % CI 2.29 to 14.49; P <0.001), after
adjusting for the day 7 lumefantrine concentration.
Among children 1–4 years of age in high transmission
areas, the risk of reinfection increased with a decrease in
WAZ (HR 1.18; 95 % CI 1.03 to 1.35 per unit change;
P = 0.017). This corresponds to a HR of 1.63 (95 % CI
1.09 to 2.44) for a child with WAZ of −3 compared
to an adequately nourished child (WAZ = 0). In high
transmission intensity areas, the estimated reinfection
rates in young children with a day 7 plasma lumefantrine
concentration of 200 ng/ml varied from 14 % for children
with WAZ of 0 to 17, 19, 22 and 26 % for children with
WAZ of −1, −2, −3 and −4, respectively (Fig. 4). In this
group of young children, age was not associated with the
risk of reinfection (P = 0.341).
Assessment of risk of bias
The risk of bias in individual studies was classified as
low (Additional file 8: Table S3). Non-randomized or un-
blinded studies were included in this analysis as this is
not considered a significant risk of bias in PK-PD studies
which explore the relationship between drug concentra-
tions and treatment response within a single treatment
arm. For these study designs, baseline characteristics across
the studies and the process of participant selection, as well
as the details of the intervention (drug, dose and duration)
are more relevant in considering the potential impact of
bias on the results. In terms of assessment of the drug con-
centrations, the blinding of all three independent outcome
laboratory assessments (namely the pharmacokinetic assays
that measure the day 7 lumefantrine concentrations, as well
as the microscopy and PCR laboratories that classify treat-
ment outcome) further reduce the risk of bias.
Sensitivity analyses showed that exclusion of any of
the studies (including those that are non-randomized or
unblinded, or used different lumefantrine assay methods)
did not change the main conclusions of the analysis (coef-
ficient of variation was 1.9 % and 5.9 % for lumefantrine
concentration and parasitemia, respectively). Similarly, the
Table 3 Cox regression analysis of risk of recrudescence by day 42 (Continued)
High/moderate TIA
< 1 year 71 2 0.80 (0.14 to 4.73) 0.807
1–4 years 973 31 1.37 (0.46 to 4.11) 0.578
5+ years 917 5 Reference
<Six-dose artemether-lumefantrine regimen 2,527 70 4.38 (1.54 to 12.49) 0.006
Early parasitological response
Fast 1,193 36 Reference
Slow 65 8 2.72 (1.04 to 7.16) 0.042
Unknown 1,269 26 1.02 (0.51 to 2.04) 0.964
aNumbers in brackets refer to patients with the symptom/characteristic present; bP value for testing the proportional hazards assumption <0.05; cfever defined as
axillary temperature >37.5 °C; donly evaluated in children <5 years of age and defined as weight-for-age Z-score (WAZ) < −2; ePRR48, parasite reduction rate at
48 hours; fslow early parasitological response was defined as parasite positivity on day 3 or loge of PRR48 < 5 (provided positive count was recorded on day 2);
g1 out of 2,528 patients with outcome were excluded from this model due to missing information on baseline parasitemia. TIA, transmission intensity area
WorldWide Antimalarial Resistance Network (WWARN)
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results were not affected by the exclusion of patients with
missing or indeterminate PCR data (multiple imputation
estimates of HR were 0.65 (95 % CI 0.56 to 0.76) and 1.76
(95 % CI 1.17 to 2.67) for log2 concentration and log10
parasitemia, respectively).
Five studies (Additional file 9: Table S4) that were not
included in the pooled analysis represent 447 patients
with day 7 concentrations measured and 14 of the re-
crudescent infections observed during follow-up. These
represent only 14 % and 16 % of the sample numbers in
all 31 studies identified, respectively. It is unlikely that
inclusion of these would have affected the results signifi-
cantly, as the aggregate data reported on their baseline
characteristics, day 7 lumefantrine concentrations and
risks of treatment failure were similar to those included in
our meta-analysis.
Discussion
In this study, the largest pooled analysis of individual
patient PK-PD data for any antimalarial to date,
artemether-lumefantrine was generally highly effective
with only 73 (3 %) P. falciparum recrudescences among
the 2,528 patients included in the treatment outcome
analysis. The most important determinants of therapeutic
response were baseline parasite density and day 7 blood or
plasma lumefantrine concentrations. Current artemether-
lumefantrine dosing recommendations achieve day 7
lumefantrine concentrations ≥200 ng/ml and >98 %
cure rates in most uncomplicated malaria patients. How-
ever, three groups were at increased risk of treatment
failure: very young children, particularly those that are
underweight-for-age; patients with high parasitemias;
and patients in areas with very low transmission intensity
Table 4 Cox regression analysis of risk of new Plasmodium falciparum infection by day 28
Parameter Patientsa Eventsa HR (95 % CI) P value
Univariable model
Day 7 lumefantrine concentration (log2)
Allb 2,528 180 0.79 (0.72 to 0.87) <0.001
Venous plasma 1,336 40 0.65 (0.56 to 0.76) <0.001
Capillary bloodb 663 130 0.87 (0.78 to 0.98) 0.002
Venous blood 529 10 0.82 (0.33 to 2.07) 0.619
Age (years) 2,528 180 0.95 (0.92 to 0.99) 0.009
Age category
< 1 year 73 9 3.51 (1.16 to 10.59) 0.026
1–4 years 1,004 148 5.01 (2.06 to 12.21) <0.001
5–11 years 540 14 2.95 (1.17 to 7.39) 0.021
12+ years 911 9 Reference
Sex (female) 2,528 (1,157) 180 (93) 1.13 (0.84 to 1.51) 0.428
WAZ 1,076 157 0.86 (0.76 to 0.97) 0.015
Underweightc 1,076 (192) 157 (37) 1.22 (0.84 to 1.79) 0.299
Transmission intensity areas (TIAs)
Very low/lowd 557 9 0.17 (0.05 to 0.51) 0.002
Moderate 721 17 0.16 (0.05 to 0.56) 0.004
High 1,070 154 Reference
Multivariable model
Day 7 lumefantrine concentration (log2)
e 2,528 180 0.70 (0.63 to 0.78) <0.001
Location/transmission intensity area (TIA)
Very low/low/moderate TIA 1,304 26 0.22 (0.06 to 0.82) 0.024
High TIA
< 1 year 57 9 0.91 (0.27 to 3.05) 0.882
1–4 years 703 138 1.35 (0.49 to 3.74) 0.565
5+ years 464 7 Reference
aNumber in brackets refers to patients with presence of the symptom/characteristic; bP value for testing proportional hazards assumption <0.05; conly evaluated in
children <5 years of age and defined as weight-for-age Z-score (WAZ) < −2; dvery low and low TIAs were combined as no new infections were observed in very
low TIA; efor concentrations measured on filter paper, the association with risk of new infection diminished after 21 days, hazard ratio = 1.062 (0.887–1.270), while
for venous plasma this remained the same over the whole period. TIA, transmission intensity area
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and slow early parasitological responses (reflecting artemi-
sinin resistance).
Young children had 17.5–52.8 % lower day 7 lumefan-
trine concentrations following supervised treatment despite
their actual mg/kg dose being higher, as they have higher
body weight normalized apparent clearance after oral
administration [35]. Optimal dosing of artemether-
lumefantrine in young children requires urgent investiga-
tion. Children under 5 years of age are at particular risk as
they account for 78 % of all malaria-related deaths [4].
Although this large pharmacokinetic data set did not
have sufficient recrudescences to confirm the trend towards
a higher risk of recrudescence among underweight young
children, this was confirmed in the larger WWARN
artemether-lumefantrine dose impact analysis. Underweight
African children between 1 and 3 years old had an in-
creased risk of recrudescence when compared with those
of the same age who were not underweight (adjusted
HR 1.66; 95 % CI 1.05 to 2.63; P = 0.028) and a 4-fold
higher risk than patients aged ≥12 years (adjusted HR
4.05; 95 % CI 1.78 to 9.18; P = 0.001) [67].
Malaria and malnutrition are common co-morbidities,
particularly in Sub-Saharan Africa, where 90 % of global
malaria deaths occur [4] and 30–33 % of children under
5 years of age are underweight [68]. However, there have
been few studies on the effect of malnutrition on mal-
aria, and these have yielded conflicting results [69–71].
The mechanisms underlying the effects of malnutrition
on antimalarial treatment response are complex and
poorly understood. Malnutrition has also been shown
to compromise the efficacy of chloroquine, sulfadoxine-
pyrimethamine, amodiaquine, dihydroartemisinin and
piperaquine [72–75]. Several physiological changes can
occur with malnutrition that may decrease drug concentra-
tions, including reduced drug absorption and/or an in-
creased volume of distribution. Malnutrition may reduce
protein binding and increase clearance, but concomitant
hepatic dysfunction may reduce the metabolism of some
drugs. The net effect is uncertain [1, 76]. In addition, the in-
nate and adaptive immune responses may be impaired by
malnutrition and micronutrient deficiencies [70, 77, 78],
which could explain the increased risk of malaria recur-
rence observed in our underweight young children even
after adjusting for their total day 7 lumefantrine concentra-
tions (unfortunately unbound lumefantrine concentrations
were not measured in any of the studies included). A
limitation of this study is that we were unable to use
the preferred anthropometric indices for determining
nutritional status [79]. As the studies pooled for this
analysis were designed to assess antimalarial efficacy,
most only recorded body weight on a single occasion and
height was only recorded in <5 % of young children. Thus
we were unable to differentiate acute under-nutrition (low
weight-for-height or BMI-for-age) from chronic under-
nutrition (low height-for-age), or distinguish tall, thin
children from short, well-proportioned children.
At currently recommended doses, the absorption of
lumefantrine appears close to saturation [40], or con-
strained by limited solubility. This was confirmed by
the small effect of body weight-adjusted (mg/kg) dose
in our study. Thus a simple increase in the number of
tablets given at each twice daily dose may not ensure
adequate lumefantrine exposure. Administering the same
recommended six doses of artemether-lumefantrine
over 5 days, dosing at 0, 8, 24, 48, 72 and 96 hours, has
been shown to increase the area under the lumefantrine
Fig. 4 Predicted reinfection rates by day 28 for a day 7 venous plasma lumefantrine concentration of 200 ng/ml. Results are shown for children
1–4 years of age in high transmission intensity areas, depending on their nutrition status (weight-for-age Z-score, WAZ). A zero study site effect
was assumed.
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concentration time-curve (AUC) in Asian adults [6, 7, 30],
but this may compromise adherence. Further studies of
higher, more frequent, or prolonged dosage regimens are
needed to determine which dosing adjustments would en-
sure that all young children, including those that are
underweight, could safely achieve the day 7 concentrations
required to achieve ≥95 % cure rates.
Achieving acceptable cure rates is particularly challenging
for underweight young children with higher parasite
densities (>100,000/uL), who require higher day 7 con-
centrations (up to 256 ng/ml). Hyperparasitemia is an
important source of antimalarial drug resistance [80] and
occurs commonly in patients with otherwise uncompli-
cated malaria. In the large WWARN pooled analysis of
14,327 patients treated with artemether-lumefantrine,
9.5 % had parasite densities above 100,000/uL [67]. This
9.5 % prevalence would be an underestimate of all un-
complicated hyperparasitemia, as the WHO recommends
excluding hyperparasitemic patients from therapeutic
efficacy studies [59]. To exclude uncomplicated hyper-
parasitemia, microscopy should be used rather than
rapid diagnostic tests when feasible, particularly in
very young and underweight children. The administra-
tion of at least two doses of parenteral artesunate is
the preferred treatment for hyperparasitemic patients [1],
and the threshold of >250,000/uL in the current WHO
definition of uncomplicated malaria in areas of moderate
to high transmission intensity [59] appears too high for
very young children, particularly if they are underweight.
The risk of artemether-lumefantrine failure was, as
expected, highest in western Cambodia, the epicenter
of antimalarial drug resistance [81, 82], where day 7
lumefantrine concentrations >1,616 ng/ml appear ne-
cessary to achieve acceptable cure rates even for very
low baseline parasite densities (<5,000/μL). It is of
concern that patients in the very low transmission areas
included in this study also required high lumefantrine
concentrations (>1,000 ng/ml) to cure even low parasite
densities. In these areas it seems unlikely that artemether-
lumefantrine dosage regimens could be adjusted to
achieve the predicted lumefantrine exposure needed to
ensure acceptable cure rates for parasite densities of up
to 100,000/μL (the WHO definition of uncomplicated
malaria in areas of low intensity malaria transmission).
The very low transmission intensity areas included in
this analysis comprised only two small studies in Thailand,
and data on the frequency of the pfmdr1 86 N allele
and copy number in our study were insufficient for de-
termining the extent to which these findings simply re-
flect high levels of lumefantrine resistance, or whether the
lack of immunity in these areas of very low transmission
intensity further compromises therapeutic efficacy. The
WWARN pooled analysis of the relationship between
lumefantrine-resistant polymorphisms in pfcrt and pfmdr1
and artemether-lumefantrine treatment response showed
that presence of the pfmdr1 gene N86 (adjusted HR 4.74;
95 % CI 2.29 to 9.78) and increased pfmdr1 copy number
(adjusted HR 6.52; 95 % CI 2.36 to 17.97) were significant
independent risk factors for recrudescence in patients
treated with artemether-lumefantrine [83].
Even after adjusting for covariates, including site ef-
fects (for Cambodia and the nearby very low intensity
transmission areas included in our study) and artemether-
lumefantrine (mg/kg) dose, slow early parasitological
treatment response more than doubled the risk of re-
crudescence. Artemether pharmacokinetic data were
not available for this pooled analysis, and previous
publications have been inconsistent. While some re-
ported that higher artemether or dihydroartemisinin
exposure was found to decrease parasite clearance
time, others have found no clinically meaningful cor-
relation between exposure and parasite clearance times
[44, 84, 85]. Whether due to artemisinin resistance and/
or inadequate artemether/dihydroartemisinin exposure,
a higher residual parasite biomass remains that the
partner lumefantrine is less able to clear. Thus ACT
treatment failure rates increase, risking the development
and spread of resistance to both the artemisinin and lume-
fantrine components. The slow parasite clearance rates
that characterize artemisinin resistance were originally
documented in western Cambodia [81, 82]. Despite con-
tainment efforts, artemisinin resistance has now been con-
firmed in five countries across mainland Southeast Asia
[86–88], where a total of 331,551 P. falciparum malaria
cases were notified in 2013 [4], highlighting the urgent
need for novel antimalarials.
The simplicity of collecting a single pharmacokinetic
sample per patient as an accurate measure of lumefan-
trine exposure is very appealing, particularly in remote
field study sites with minimal infrastructure. The feasi-
bility of pharmacokinetic sampling is further enhanced
by the use of capillary blood specimens dried on filter
paper, although this method is more vulnerable to in-
ter-operator variability and the effects of anemia. This
pooled analysis shows that this matrix is less optimal, be-
ing 2- to 3-fold more variable, and 5-fold less sensitive.
However, with the therapeutic threshold of 200 ng/ml,
the filter paper limit of quantification of 25 ng/ml should
be sufficient for the measurements of day 7, if not later,
concentrations. Careful attention to dried blood spot
sample collection methods may reduce inter-operator
variability.
As the determinants of therapeutic response are multi-
factorial, studies of the pharmacokinetics of antimalarial
drugs often have inadequate power to define optimal dos-
age recommendations. Pooled individual patient PK-PD
data analysis makes the best use of available data for dis-
tinguishing treatment failures resulting from inadequate
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drug exposure from those caused by drug-resistant para-
sites. The main limitation of pooling individual patient
pharmacokinetic data is differences in assay methods be-
tween studies. Only two of the studies included in this
pooled analysis [42, 44] used mass spectrometry to deter-
mine lumefantrine concentrations; early attempts failed
due to matrix effects [40]. More recently, several tandem
mass spectrometry methods reported having addressed
this issue [42, 51, 89]. The risks of one study compromis-
ing the overall results of a pooled analysis decrease as the
number of studies included increase; in our sensitivity
analysis excluding each study one at a time, no individual
study was shown to be influential and the main results
were shown to be highly robust. Heterogeneity can be re-
duced by method standardization following the WHO/
WWARN consensus document, Methods and techniques
for assessing exposure to antimalarial drugs in clinical
field studies [90]. The WWARN reference material pro-
gram and, for more stable antimalarial medicines, external
proficiency testing have further contributed to reducing
inconsistency between antimalarial assays [91].
Dose optimization is best informed when the pharma-
cokinetic parameters that drive artemether-lumefantrine
exposure, particularly bioavailability (including doses above
which absorption becomes saturated), volume of distribu-
tion and clearance, are characterized adequately in patients
with uncomplicated malaria, including high-risk popula-
tions. Thus all available drug concentration-over-time data,
and not just day 7 concentrations, need to be analyzed
using a population PK-PD model. In collaboration with re-
searchers worldwide, WWARN has obtained data from
4,122 malaria patients with a total of 9,258 lumefantrine
concentrations (Fig. 1). This WWARN study group will
continue to explore this expanded data set to answer key
questions more fully, such as: ‘can Day 7 lumefantrine con-
centrations serve as a convenient surrogate for AUCs in all
key target populations?’; ‘what proportion of treatment
failures are explained by inadequate drug exposure?’; and
‘which modified dosage regimens should be investigated for
important target populations, such as pregnant women,
underweight young children or patients with co-morbid
conditions (such as HIV/AIDS), or those who are taking
drugs that reduce antimalarial exposure (such as efavirenz
or rifampicin)?’.
Conclusions
This study provides a day 7 blood or plasma concentration
threshold for evaluating whether individual treatment
failures reflect inadequate drug exposure or parasite
resistance, comparing artemether-lumefantrine formula-
tions, and informing optimal artemether-lumefantrine dos-
ing regimens. Although current dosing recommendations
are adequate for most patients with acute P. falciparum
malaria, three patient groups are at increased risk of
treatment failure: very young children, particularly those
that are underweight-for-age; patients with high parasite-
mias; and patients in very low transmission intensity areas
with emerging parasite resistance. Treatment adherence
and response should be monitored more closely, and
higher, more frequent, or prolonged dosage regimens need
to be evaluated in very young children, particularly if mal-
nourished, and in patients with hyperparasitemia. Novel
antimalarials are needed for very low transmission inten-
sity areas with emerging artemisinin resistance.
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